Tatva Chintan Pharma Chem Ltd. is launching its IPO. The Rs. 500 crore public offer comprises a fresh issue of equity shares aggregating up to Rs. 225 crores and an offer for sale of equity shares aggregating up to Rs. 275 crores.
About the company:
Tatva Chintan Pharma Chem Ltd. is a specialty chemicals manufacturing company. It is the largest and only commercial manufacturer of structure-directing agents (SDAs) for zeolites in India, and also enjoys the second-largest position globally.
Along with SDAs, the company is also engaged in the manufacture of phase transfer catalysts (PTCs), pharmaceutical and agrochemical intermediates, and other specialty chemicals which have applications across various industries such as the automotive, petroleum, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care and flavor and fragrances industries.
Apart from India, the company also exports its products to over 25 countries, including the USA, China, Germany, Japan, South Africa, and the UK. During the Fiscals ended March 31, 2021, exports of products amounted to 70.58%, of the companies revenue.
Financial Snapshot:
| Financial Year Ended | Revenue (₹ Crores) | PAT (₹ Crores) | EPS (₹) |
|---|---|---|---|
| March 2019 | 206.80 | 20.54 | 10.23 |
| March 2020 | 264.62 | 37.79 | 18.81 |
| March 2021 | 306.29 | 52.26 | 26.02 |
IPO Schedule:
| Event | Date |
|---|---|
| Issue Period | 16th July 2021 to 20th July 2021 |
| Price Range | ₹ 1073 - 1083 |
| Minimum Bid Quantity | 13 |
| Finalisation of Allotment | 26th July 2021 |
| Initiation of Refunds | 27th July 2021 |
| Credit of Shares | 28th July 2021 |
| Listing Date | 29th July 2021 |
| Mandate End Date | 5th August 2021 |
How do I apply to the Tatva Chintan Pharma Chem IPO?
You can apply for the Tatva Chintan Pharma Chem IPO using any supported UPI app by following two steps:
- Enter your bid on Console .
- Accept UPI mandate on your phone.
On acceptance of the mandate, the bid amount will get blocked in your bank account. Click here to learn more.